{"brief_title": "Safety and Efficacy of PRO 542 in the Treatment of HIV-Infected Patients", "brief_summary": "The purpose of this study is to determine any adverse effects of PRO 542 after administration and to determine the anti-HIV effects of PRO 542 in the patient.", "detailed_description": "A 2 arm study involving a series of 3 triweekly doses of PRO 542. One arm will involve patients on a stable dose of anti-retroviral therapy and the other arm will consist of patients not receiving anti-retroviral therapy. Three patients will be enrolled in each arm followed by a safety evaluation. Following the safety evaluation, 3 more patients may be enrolled in each arm. After the first 12 patients, an additional 12 patients may be enrolled pending safety data.", "condition": ["HIV Infections", "Acquired Immune Deficiency Syndrome"], "intervention_type": ["Drug"], "intervention_name": ["CD4-IgG2 (PRO 542)"], "criteria": "Inclusion Criteria: - Confirmed diagnosis of HIV - Patients must be on a stable dose of acceptable anti-HIV therapy or receiving no anti-HIV therapy for at least four (4) weeks prior to the start of this study - HIV-1 determination by RNA-PCR greater than or equal to 100,000 copies/ml - CD4 count >50/cubic mm at screening Exclusion Criteria: - Patients who have previously received PRO 542 - Patients with active, significant infection (other than HIV) not controlled by antibiotics - Pregnant or lactating women - Patients with an estimated life expectancy of <3 months - Patients currently receiving steroids or other immunosuppressive therapy or immunoglobulin therapy except for topical or inhaled steroids - Patients with known allergy or hypersensitivity to PRO 542 or immunoglobulin preparations", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Treatment Experienced", "mesh_term": ["HIV Infections", "Immunologic Deficiency Syndromes", "Acquired Immunodeficiency Syndrome", "CD4 Immunoadhesins"], "id": "NCT00055185"}